SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2005
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
For Immediate Release 2 September, 2005
DATE OF RELEASE OF INTERIM RESULTS
FOR THE SIX MONTHS ENDING 30 JUNE 2005
UPDATE ON FLUTIFORM™ NEGOTIATIONS
LONDON, UK, 2 September 2005 - SkyePharma plc (LSE: SKP, NASDAQ: SKYE) will announce its Interim results for the six
months ending 30 June 2005 on Wednesday 28 September 2005. These results will be the first presented under International
Financial Reporting Standards.
SkyePharma announced at the end of April that it had negotiated Heads of Terms with a major global pharmaceutical
company for the US rights to Flutiform™. SkyePharma has now discontinued contract negotiations with that party.
However, as indicated in July, the April announcement created considerable competitive interest in acquiring rights to
Flutiform™. As a result, SkyePharma remains in active negotiations with several companies, including advanced
discussions with another major global pharmaceutical company for worldwide rights to Flutiform™.
Michael Ashton, SkyePharma's Chief Executive, said: "Flutiform™'s prospects continue to improve as we believe
its profile will make it superior to competing products in this fast-growing market, already worth more than
$5 billion. A number of companies remain actively interested in licensing the product, within a variety of commercial
structures including the retention of co-promotion rights by SkyePharma. Progress towards filing of Flutiform™
remains on track and Phase III trials are planned to commence early next year. With estimated peak sales of Flutiform™
well in excess of $1 billion, we remain convinced of our ability to deliver significant value to our shareholders."
For further information please contact:
SkyePharma PLC +44 207 491 1777
Michael Ashton, Chief Executive Officer
Peter Laing, Director of Corporate Communications +44 207 491 5124
Sandra Haughton, US Investor Relations +1 212 753 5780
Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich
Notes for editors:
About SkyePharma
SkyePharma develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide
easier-to-use and more effective drug formulations. There are now eleven approved and marketed products incorporating
SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced
solubilisation capabilities. For more information, visit www.skyepharma.com.
About Flutiform™
Flutiform™ is a fixed-dose combination of the inhaled corticosteroid fluticasone with the long-acting
bronchodilator formoterol in an HFA-powered metered-dose aerosol inhaler. Flutiform™, which is designed for
the treatment of asthma and chronic obstructive pulmonary disease (COPD), has completed Phase II development.
Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour
provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations
reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will
materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly
from those expressed or implied by the forward-looking statements based upon a number of factors, which are described
in SkyePharma's 20-F and other documents on file with the SEC. Factors that could cause differences between actual
results and those implied by the forward-looking statements contained in this news release include, without
limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory
approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's
ability to manufacture products on a large scale or at all, risks related to SkyePharma's and its marketing
partners' ability to market products on a large scale to maintain or expand market share in the face of changes in
customer requirements, competition and technological change, risks related to regulatory compliance, the risk of
product liability claims, risks related to the ownership and use of intellectual property, and risks related to
SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking
statement to reflect events or circumstances after the date of this release.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ Douglas Parkhill
Name: Douglas Parkhill
Title:
Company Secretary
Date: September 2, 2005